These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 10587034)

  • 1. Fludarabine phosphate as an active and well tolerated salvage therapy in an elderly heavily pretreated Hodgkin's disease patient: a case report.
    Bordonaro R; Ferraù F; Giuffrida D; Calì S; Priolo D; Colina P; Ursino M; Failla G
    Tumori; 1999; 85(4):288-9. PubMed ID: 10587034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
    O'Connor OA; Lue JK; Sawas A; Amengual JE; Deng C; Kalac M; Falchi L; Marchi E; Turenne I; Lichtenstein R; Rojas C; Francescone M; Schwartz L; Cheng B; Savage KJ; Villa D; Crump M; Prica A; Kukreti V; Cremers S; Connors JM; Kuruvilla J
    Lancet Oncol; 2018 Feb; 19(2):257-266. PubMed ID: 29276022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
    Carella AM; Cavaliere M; Lerma E; Ferrara R; Tedeschi L; Romanelli A; Vinci M; Pinotti G; Lambelet P; Loni C; Verdiani S; De Stefano F; Valbonesi M; Corsetti MT
    J Clin Oncol; 2000 Dec; 18(23):3918-24. PubMed ID: 11099321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma.
    Hänel M; Kröger N; Kroschinsky F; Birkmann J; Hänel A; Herbst R; Naumann R; Friedrichsen K; Ehninger G; Zander AR; Fiedler F
    J Cancer Res Clin Oncol; 2001; 127(6):387-95. PubMed ID: 11414199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
    Hendry L; Bowen A; Matutes E; Swansbury J; Catovsky D
    Leuk Lymphoma; 2004 May; 45(5):945-50. PubMed ID: 15291353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphomas: a phase II study of the German Low-Grade Non-Hodgkin's Lymphoma Study Group.
    Hiddemann W; Unterhalt M; Pott C; Wörmann B; Sandford D; Freund M; Engert A; Gassmann W; Holtkamp W; Seufert J
    Semin Oncol; 1993 Oct; 20(5 Suppl 7):28-31. PubMed ID: 8235693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fludarabine: a review of its use in non-Hodgkin's lymphoma.
    Anderson VR; Perry CM
    Drugs; 2007; 67(11):1633-55. PubMed ID: 17661532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin's disease.
    Devizzi L; Santoro A; Bonfante V; Viviani S; Balzarini L; Valagussa P; Bonadonna G
    Ann Oncol; 1994 Nov; 5(9):817-20. PubMed ID: 7531487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage chemotherapy using a combination of fludarabine and cyclophosphamide for refractory or relapsing indolent and aggressive non-Hodgkin's lymphomas.
    Lossos IS; Paltiel O; Polliack A
    Leuk Lymphoma; 1999 Mar; 33(1-2):155-60. PubMed ID: 10194133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fludarabine, mitoxantrone and dexamethasone as front-line therapy in elderly patients affected by newly-diagnosed, low-grade non-Hodgkin's lymphomas with unfavorable prognostic factors: results of a phase II study.
    Bordonaro R; Petralia G; Restuccia N; Todaro AM; Serraino D; Giuffrida D; Cordio S; Giannitto-Giorgio C; Salice P; Ursino M; Novello G; Marletta F; Manusia M
    Leuk Lymphoma; 2004 Jan; 45(1):93-100. PubMed ID: 15061203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.
    Josting A; Rudolph C; Reiser M; Mapara M; Sieber M; Kirchner HH; Dörken B; Hossfeld DK; Diehl V; Engert A;
    Ann Oncol; 2002 Oct; 13(10):1628-35. PubMed ID: 12377653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Moskowitz CH; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Gianni AM; Carella A; Osmanov D; Bachanova V; Sweetenham J; Sureda A; Huebner D; Sievers EL; Chi A; Larsen EK; Hunder NN; Walewski J;
    Lancet; 2015 May; 385(9980):1853-62. PubMed ID: 25796459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
    Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
    Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC): a highly active regimen for advanced and poor-prognosis Hodgkin's disease.
    Wiernik PH; Dutcher JP; Einzig AI; Sparano J; Frank M; Friedenberg W
    Cancer J Sci Am; 1998; 4(4):254-60. PubMed ID: 9689984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease.
    Anderlini P; Giralt S; Andersson B; Ueno NT; Khouri I; Acholonu S; Cohen A; Körbling MJ; Manning J; Romaguera J; Sarris A; Rodriguez ; Hagemeister F; Mclaughlin P; Cabanillas F; Champlin RE
    Bone Marrow Transplant; 2000 Sep; 26(6):615-20. PubMed ID: 11041566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy.
    Keating MJ; O'Brien S; Lerner S; Koller C; Beran M; Robertson LE; Freireich EJ; Estey E; Kantarjian H
    Blood; 1998 Aug; 92(4):1165-71. PubMed ID: 9694704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of fludarabine in refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma--the Jerusalem experience.
    Gillis S; Dann EJ; Cass Y; Rochlemer RR; Polliack A
    Leuk Lymphoma; 1994 Sep; 15(1-2):173-5. PubMed ID: 7858497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy.
    Devillier R; Coso D; Castagna L; Brenot Rossi I; Anastasia A; Chiti A; Ivanov V; Schiano JM; Santoro A; Chabannon C; Balzarotti M; Blaise D; Bouabdallah R
    Haematologica; 2012 Jul; 97(7):1073-9. PubMed ID: 22271893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variant Richter's syndrome: a rare case of classical Hodgkin's lymphoma developing in a patient with chronic lymphocytic leukemia treated with fludarabine.
    Nemets A; Ben Dor D; Barry T; Ducach A; Blumental R; Ben Alon D; Lugassy G
    Leuk Lymphoma; 2003 Dec; 44(12):2151-4. PubMed ID: 14959863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.